(NASDAQ: ACHV) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Achieve Life Sciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ACHV's revenue for 2026 to be $608,723,014, with the lowest ACHV revenue forecast at $520,276,080, and the highest ACHV revenue forecast at $697,169,947. On average, 2 Wall Street analysts forecast ACHV's revenue for 2027 to be $3,357,514,970, with the lowest ACHV revenue forecast at $3,121,656,480, and the highest ACHV revenue forecast at $3,593,373,459.
In 2028, ACHV is forecast to generate $7,977,566,560 in revenue, with the lowest revenue forecast at $7,977,566,560 and the highest revenue forecast at $7,977,566,560.